TY - JOUR T1 - SERVİKAL SİTOLOJİSİ NORMAL OLUP,HPV 16 VE 18 GENOTİPİ DIŞI HPV ENFEKSİYONU BULUNAN HASTALARDAKİ KOLPOSKOPİ SONUÇLARI AU - Şahin, H.öztürk AU - Gürlek, Beril AU - Arslan, Halit PY - 2019 DA - December JF - Türk Jinekolojik Onkoloji Dergisi JO - TRSGO Dergisi PB - Türk Jinekolojik Onkoloji Derneği WT - DergiPark SN - 2148-5372 SP - 6 EP - 9 VL - 21 IS - 1 LA - tr AB - AMAÇLiteratürdeki güncel gelişmeler ,normal sitolojidebulunan HPV(Human Papilloma Virus) tip 16 ve 18 dışındakigenotiplerde servikal intraepitelyal lezyon (SIL) görülme risk analizi çalışmalarına önem kazandırmıştır.Bizdeçalışmamızda bu hasta grubunda yaptığımız kolposkopi eşliğindeki biopsi sonuçlarınıinceledik.GEREÇ VE YÖNTEMÇalışmamıza , Mayıs 2016-2018 tarihleri arasında servikal sitolojisi normalolup,tekli yada çoklu HPV enfeksiyonu bulunmasına göre kategorize edilen 16 ve18 dışı yüksek riskli HPV (hr-HPV)pozitifliği bulunan 104 hasta dahil edildi. Tüm hastalardan histolojik tanı için kolposkopi eşliğindebiopsi alındı.Sitolojik inceleme Bethesta metodu ile klasifiye edilirken,HPVDNA analizi Hybrid Capture 2 yöntemi ileyapıldı.SONUÇLAR104 hastamızın 59’unda (%56,7)displazi saptanmazken,33’ünde (%31,7) CIN1,12’sinde(%11,5) ≥CIN 2 saptandı.Çoklu HPV enfeksiyonunun SIL riskini arttırmadığı görüldü.≥CIN 2saptanan 12 vakamızın 8’i(%66,6) HPV 31 genotipindeydi.TARTIŞMAHPV genotiplerinin risk skorlama çalışmaları,normalsitolojisi bulunan hastalarda doğrudan kolposkopiye refere edilecek hastaların triajını değiştirebilir. KW - 16/18 DIŞI HPV KW - NORMAL SİTOLOJİ KW - KOLPOSKOPİ CR - 1. H. zur Hausen . Papillomaviruses and cancer: from basic studies to clinical application Nature Rev Cancer, 2 (2002), pp. 350-392 CR - 2. National Cancer Institute at the National Institutes of Health (2018): Cervical Cancer Screening. [https://www.cancer. gov/types/cervical/hp/cervical-screening pdq#link/_133_ toc]. CR - 3. Cuzick J, Clavel C, Petry KU, et al. Overview of the European andNorth American studies on HPV testing in primary cervical cancerscreening. Int J Cancer. 2006;119:1095–1101 CR - 4. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding humanpapillomavirus testing in secondary prevention of cervical cancer.Vaccine. 2012;30:F88–F99. CR - 5. L.S. Massad, M.H. Einstein, W.K. Huh,et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors J. Low. Genit. Tract Dis., 17 (2013), pp. S1-s27 CR - 6. Franco E, Villa LL, Sobrinho JP, et al. Epidemiology of acquisitionand clearance of cervical human papillomavirus infect ion in womenfrom a high-risk area for cervical cancer. J Infect Dis. 1999; 180:1415–1423 CR - 7. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at recruitmentfrom a randomized controlled trial comparing human papillomavirustesting alone with conventional cytology as the primary cervicalcancer screening test. J Natl Cancer Inst. 2008; 100:492–501. CR - 8. Cox JT, Schiffman M, Solomon D. ASCUS-LSIL Triage Study (ALTS)Group. Prospective follow-up suggests similar risk of subsequentcervical intraepithelial neoplasia grade 2 or 3 among women withcervical intraepithelial neoplasia grade 1 or negative colposcopy anddirected biopsy. Am J Obstet Gynecol. 2003; 188:1406. CR - 9. W.C. Reeves, L.A. Brinton, M. Garcia, M.M. Brenes Human papillomavirus infection and cervical cancer in Latin America N Engl J Med, 320 (22) (1989), pp. 1437-1441 CR - 10. F.X. Bosch, N. Munoz, S.D. Sanjose, et al .Risk factors for cervical cancer in Columbia and Spain Int J Cancer, 52 (1992), pp. 750-758 CR - 11. Eluf-Neto, M. Booth, N. Munoz,et al .Human papillomavirus and invasive cervical cancer in Brazil Br J Cancer, 69 (1994), pp. 114-119 CR - 12. M.T. Kouri, S. Morsberger, A. Carrillo,et al.HPV prevalence among Mexican women with neoplastic and normal cervices Gynaecol Oncol, 70 (1998), pp. 115-120 CR - 13. S. Chinchareon, R. Herrero, N. Munoz,et al.Risk factors for cervical cancer in Thailand: a case control study J Natl Cancer Inst, 90 (1) (1998), pp. 50-57 CR - 14. F.X. Bosch, N. Munoz, S.D. Sanjose Human papillomavirus and the other risk factors for cervical cancer Biomed Pharmacother, 51 (1997), pp. 268-275 CR - 15. W.K. Huh, K.A. Ault, D. Chelmow,et al.Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance J. Low. Genit. Tract Dis., 19 (2015), pp. 91-96 CR - 16. P.E. Castle, M.H. Stoler, T.C. Wright Jr., A. Sharma, T.L. Wright, C.M. Behrens Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study Lancet Oncol., 12 (2011), pp. 880-890 CR - 17. H.A. Katki, M. Schiffman, P.E. Castle,et al.Benchmarking CIN 3+ risk as the basis for incorporating HPV and pap cotesting into cervical screening and management guidelines J. Low. Genit. Tract Dis., 17 (2013), pp. S28-S35 CR - 18. Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combi-nation with liquid-based cytology in primary cervical screening(ARTISTIC): a randomised controlled trial. Lancet Oncol. 2009;10:672Y82 CR - 19. Castillo M, Astudillo A, Clavero O, et al (2016). Poor cervical cancer screening attendance and false negatives. A call for organized screening. PLoS One, 11, e0161403. CR - 20. J. Berkhof, N.W. Bulkmans, M.C. Bleeker,et al.Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear Cancer Epidemiology, Biomarkers & Prevention: a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 15 (2006), pp. 1268-1273 CR - 21. S.K. Kjaer, K. Frederiksen, C. Munk, T. Iftner Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence J. Natl. Cancer Inst., 102 (2010), pp. 1478-1488 CR - 22. J. Monsonego, J.T. Cox, C. Behrens,et al.Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: data from the ATHENA trial Gynecol. Oncol., 137 (2015), pp. 47-54 CR - 23. M. Schiffman, R.D. Burk, S. Boyle,et al.A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results J. Clin. Microbiol., 53 (2015), pp. 52-59 CR - 24. M. Schiffman, N. Hyun, T.R. Raine-Bennett,et al.A cohort study of cervical screening using partial HPV typing and cytology triage Int. J. Cancer, 139 (2016), pp. 2606-2615 CR - 25. L.T. Thomsen, K. Frederiksen, C. Munk, J. Junge, T. Iftner, S.K. Kjaer Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology Int. J. Cancer, 137 (2015), pp. 193-203 CR - 26. C.M. Wheeler, W.C. Hunt, J. Cuzick, E. Langsfeld, M. Robertson, P.E. Castle The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: a population-based study of opportunistic cervical screening in the United States Int. J. Cancer, 135 (2014), pp. 624-634 CR - 27. Aydoğmuş H, Aydoğmuş S. Comparison of Colposcopic Biopsy Results of Patients Who have Cytomorphological Normal but HPV 16-18 or Other High-Risk HPV Subtypes Positive. Asian Pac J Cancer Prev. 2019 Feb 26;20(2):417-420. PubMed PMID:30803201. CR - 28.Karaca İ,Öztürk M,Comba C, et al.İmmediate biopsy of cytology-negative and non-HPV-16/18 oncogenic types positive patients.Diagnostic Cytopathology.2018;46:326-330. CR - 29. Stoler MH, Wright TC Jr, Parvu V, Yanson K, Cooper CK, Andrews J. Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, ≥25 years of age, with NILM cytology. Gynecol Oncol. 2019 Apr;153(1):26-33. doi: 10.1016/j.ygyno.2018.12.024. Epub 2019 Jan 10. PubMed PMID: 30638767. UR - https://dergipark.org.tr/en/pub/trsgo/article/569925 L1 - https://dergipark.org.tr/en/download/article-file/876874 ER -